Insulin‐like growth factor‐binding protein‐2 in patients with prostate carcinoma and benign prostatic hyperplasia

Abstract

Several autoimmune diseases, mainly autoantibody-mediated, are attenuated by infusion of total IgG (IVIg). The efficacy varies widely from one patient to another. Using an experimental model of in vitro phagocytosis of autoanti-body-coated erythrocytes by mouse macrophages, we analysed the possible causes for such a variability. Our results indicated that the efficacy of the phagocytosis inhibition depends upon different factors, such as the isotype and the extent of polymerization of the immunoglobulin used for the treatment as well as the genetic background of the mice and the state of macroph-age activation that can be influenced by concomitant viral infection. The development of an in vitro assay for the phagocytic activity of macrophages might improve the selection of patients susceptible to benefit from IVIg treatment.

Picogram doses of lipopolysaccharide exacerbate antibody‐mediated thrombocytopenia and reduce the therapeutic efficacy of intravenous immunoglobulin in mice

“…Interestingly, similar observations were made in a mouse model of haemolytic anaemia (Meite et al , 2000), suggesting that the LPS exacerbating effect may not be restricted to opsonized platelet destruction. In addition, in vitro assays showed that the suppressive effect of IVIg on the phagocytosis of opsonized red cells was greatly compromised when macrophages from virus‐infected mice were used (Leonard et al , 2006), a finding similar to the in vivo effects of LPS on IVIg efficacy reported in the present study. Additional work will be required to assess the potential impacts of these findings on the clinical management of ITP patients.…”